Harmine mediated neuroprotection via evaluation of glutamate transporter 1 in a rat model of global cerebral ischemia

Neuroscience Letters

Volumn 583, Issue , 2014, Pages 32-36

  Sun, Piyun ^a   Zhang, Shuyan ^a   Li, Yanyan ^b   Wang, Lihua ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Mudanjiang Second People's Hospital   (China)

Author keywords

Astrocyte activation; Functional recovery; GCI; GLT 1; Harmine

Indexed keywords

DIHYDROKAINIC ACID; HARMINE; MESSENGER RNA; NEUROPROTECTIVE AGENT; VESICULAR GLUTAMATE TRANSPORTER 1; EXCITATORY AMINO ACID TRANSPORTER 2; KAINIC ACID; SLC1A2 PROTEIN, RAT;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CELL ACTIVATION; CELL DEATH; CELL SURVIVAL; CELL VOLUME; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG DETERMINATION; DRUG EFFECT; DRUG SCREENING; FEMALE; GLOBAL CEREBRAL ISCHEMIA; IMMUNOFLUORESCENCE; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; RNA ISOLATION; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; ASTROCYTE; BRAIN CORTEX; BRAIN INFARCTION; DRUG EFFECTS; GENETICS; INTRAPERITONEAL DRUG ADMINISTRATION; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ASTROCYTES; BRAIN INFARCTION; BRAIN ISCHEMIA; CELL SURVIVAL; CEREBRAL CORTEX; EXCITATORY AMINO ACID TRANSPORTER 2; FEMALE; HARMINE; INJECTIONS, INTRAPERITONEAL; KAINIC ACID; NEURONS; NEUROPROTECTIVE AGENTS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER;

EID: 84907470255     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.09.023     Document Type: Article

References (26)

1. Anderson M.F., Blomstrand F., Blomstrand C., Eriksson P., Nilsson M. Astrocytes and stroke: networking for survival?. Neurochem. Res. 2003, 28:293-305.
2. Astulla A., Zaima K., Matsuno Y., Hirasawa Y., Ekasari W., Widyawaruyanti A., Zaini N.C., Morita H. Alkaloids from the seeds of Peganum harmala showing antiplasmodial and vasorelaxant activities. J. Nat. Med. 2008, 62:470-472.
3. Bederson J.B., Pitts L.H., Germano S., Nishimura M., Davis R., Bartkowski H. Evaluation of 2,3,5-triphenyltetrazolium chloride as a stain for detection and quantification of experimental cerebral infarction in rats. Stroke 1986, 17:1304-1308.
4. Bederson J.B., Pitts L.H., Tsuji M., Nishimura M., Davis R., Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986, 17:472-476.
5. Benveniste H., Drejer J., Schousboe A., Diemer N.H. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 1984, 43:1369-1374.
6. Bunch L., Erichsen M.N., Jensen A.A. Excitatory amino acid transporters as potential drug targets. Expert Opin. Ther. Targets 2009, 13:719-731.
7. Cui C., Cui Y., Gao J., Sun L., Wang Y., Wang K., Li R., Tian Y., Song S., Cui J. Neuroprotective effect of ceftriaxone in a rat model of traumatic brain injury. Neurol. Sci. 2014, 35:695-700.
8. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 2001, 65:1-105.
9. Farzin D., Mansouri N. Antidepressant-like effect of harmane and other β-carbolines in the mouse forced swim test. Eur. Neuropsychopharmacol. 2006, 16:324-328.
10. Guan Y., Louis E.D., Zheng W. Toxicokinetics of tremorogenic natural products, harmane and harmine, in male Sprague-Dawley rats. J. Toxicol. Environ. Health A 2001, 64:645-660.
11. Harvey B.K., Airavaara M., Hinzman J., Wires E.M., Chiocco M.J., Howard D.B., Shen H., Gerhardt G., Hoffer B.J., Wang Y. Targeted over-expression of glutamate transporter 1 (GLT-1) reduces ischemic brain injury in a rat model of stroke. PLoS ONE 2011, 6:22135.
12. Huang K., Kang M.H., Askew C., Kang R., Sanders S.S., Wan J., Davis N.G., Hayden M.R. Palmitoylation and function of glial glutamate transporter-1 is reduced in the YAC128 mouse model of Huntington disease. Neurobiol. Dis. 2010, 40:207-215.
13. Lauderback C.M., Hackett J.M., Huang F.F., Keller J.N., Szweda L.I., Markesbery W.R., Butterfield D.A. The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Aβ1-42. J. Neurochem. 2001, 78:413-416.
14. Li Y., Sattler R., Yang E.J., Nunes A., Ayukawa Y., Akhtar S., Ji G., Zhang P.-W., Rothstein J.D. Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression. Neuropharmacology 2011, 60:1168-1175.
15. Moura D.J., Richter M.F., Boeira J.M., Henriques J.A.P., Saffi J. Antioxidant properties of β-carboline alkaloids are related to their antimutagenic and antigenotoxic activities. Mutagenesis 2007, 22:293-302.
16. Pekny M., Nilsson M. Astrocyte activation and reactive gliosis. Glia 2005, 50:427-434.
17. Rauen T., Kanner B.I. Localization of the glutamate transporter GLT-1 in rat and macaque monkey retinae. Neurosci. Lett. 1994, 169:137-140.
18. Rothstein J.D., Dykes-Hoberg M., Pardo C.A., Bristol L.A., Jin L., Kuncl R.W., Kanai Y., Hediger M.A., Wang Y., Schielke J.P. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 1996, 16:675-686.
19. Rothstein J.D., Van Kammen M., Levey A.I., Martin L.J., Kuncl R.W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 1995, 38:73-84.
20. Samuelsson C., Kumlien E., Flink R., Lindholm D., Ronne-Engström E. Decreased cortical levels of astrocytic glutamate transport protein GLT-1 in a rat model of posttraumatic epilepsy. Neurosci. Lett. 2000, 289:185-188.
21. Sheardown M.J., Nielsen E.O., Hansen A.J., Jacobsen P., Honore T. 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo (F) quinoxaline: a neuroprotectant for cerebral ischemia. Science 1990, 247:571-574.
22. Siesjö B.K. Mechanisms of ischemic brain damage. Crit. Care Med. 1988, 16:954-963.
23. Simon R., Swan J., Griffiths T., Meldrum B. Blockade of N-methyl-d-aspartate receptors may protect against ischemic damage in the brain. Science 1984, 226:850-852.
24. Sourkes T.L. Rational hope in the early treatment of Parkinson's disease. Can. J. Physiol. Pharmacol. 1999, 77:375-382.
25. Verma R., Mishra V., Sasmal D., Raghubir R. Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury. Eur. J. Pharmacol. 2010, 638:65-71.
26. Wang R., Tu J., Zhang Q., Zhang X., Zhu Y., Ma W., Cheng C., Brann D.W., Yang F. Genistein attenuates ischemic oxidative damage and behavioral deficits via eNOS/Nrf2/HO-1 signaling. Hippocampus 2013, 23:634-647.